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Abstract. Human linear chromosomes are capped by
specialized DNA-protein structures called telomeres. The
present study analysed the telomerase activity, hTERT protein
and telomere length in meningiomas and gliomas in relation
to their WHO grading. Fifty-three freshly dissected tumour
biopsies were analysed for telomerase activity, hTERT protein
expression and telomere length. Telomerase activity was
examined in 41 of the 53 biopsies. Telomerase activity was
detected in 3 of 35 (8.6%) screened meningiomas (1 benign,
1 atypical and 1 malignant meningioma). For hTERT
expression, 56.4% of meningiomas were positive with a mean
labelling index (hTERT LI) of 31.3% (SD=26.5) for the
hTERT positive meningiomas. The mean telomere length for
meningiomas was 6.983 kb (SD=1.969). For gliomas, no
active telomerase was detected in 2 low-grade astrocytomas,
whereas three of the four screened glioblastomas were
positive for telomerase activity. The only hTERT protein
positive astrocytoma had a mean labelling index of 9.0%. On
the other hand, the hTERT LI for glioblastomas was 53.6%
(SD=28.0). The two low-grade astrocytomas had a telomere
length of 14.310 and 9.236 kb. The anaplastic astrocytoma
had a telomere length of 4.903 kb and the glioblastomas
5.767 kb (SD=2.042). The normal meningeal and neuronal
tissue is negative for telomerase activity and hTERT. The
length was ±10.000 kb. These results indicate that telomere
shortening may be a critical step in pathogenesis of atypical
and malignant meningiomas and gliomas. Critical telomere
shortening in vitro was shown to activate telomerase.
Introduction
Telomeres play an essential role in maintaining the stability
and integrity of chromosomes (1,2). They consist of TTAGGG
tandem repeats (3). Telomeres gradually shorten with each
cell division in vitro and telomere length is shown to decrease
with age in vivo (2,4). This shortening of telomeres may be a
mitotic clock for cells leading to senescence and apoptosis
(5,6). Normal human cells shorten their telomeres until they
reach a critical length (~4 kb). In some instances, by chromo-
somal instability, cells escape from apoptosis leading to
indefinite life span by activating telomerase (7,8). Telomerase
is a ribonucleoprotein enzyme complex that synthesizes
telomeric repeats at the chromosomal ends (4). Two major
components of the telomerase complex are hTERT (human
telomerase reverse transcriptase) and an RNA template
(9,10). If tumour cells turn on telomerase, the expression of
this enzyme may lead to unlimited proliferation and
immortality for tumour cells (11). Some results have already
been published on telomerase and telomeres in intracranial
tumours (12-14), showing a correlation between telomerase
activity and histopathological grading. It has been reported
that hTERT rather than telomerase activity could be used as a
prognostic marker for progression and potential recurrence
(15-17). Moreover, hTERT could be considered as an early
signal towards indefinite life span (18). Telomere length can
be seen as the result of the interaction between active
telomerase and the telomeric DNA ends (19). This length is
crucial for the protection of the chromosomes (1). In our
previous studies, we found a lack of telomerase activity and
low hTERT-protein expression in benign meningiomas in
comparison to malignant tumours (18,20). In the present
study, we examined the telomerase activity, the hTERT
protein expression and the telomere length in intracranial
tumours to see if there is any difference between benign,
malignant and normal intracranial tissue and if tumours
without telomerase activity also have attritions or aberrations
in their telomere length.
Materials and methods
Surgical specimen. Biopsies of 53 intracranial tumours
including 39 meningiomas [34 WHO (World Health
Organization) grade I meningiomas, 3 atypical WHO grade II
meningiomas and 2 malignant WHO grade III meningiomas]
and 14 gliomas (2 low-grade WHO grade II astrocytomas,
1 anaplastic WHO grade III astrocytoma and 11 WHO grade
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IV glioblastoma multiforme) were collected from the
University Hospital, St. Lucas Hospital and Maria-Middelares,
Ghent, Belgium. There were 34 women and 19 men with a
median age of 56.7 (range 31-81). The classification and
grading of the tumours was performed by the pathologists
based on the WHO criteria (21). Immediately after surgery,
the tumour fragments were transferred into vials containing
Minimal Essential Medium (MEM, Invitrogen, Merelbeke,
Belgium) for transport. One part was used for histopatho-
logical diagnosis and a second part was conserved in liquid
nitrogen for molecular analysis of telomerase activity and
measurement of telomere length. This research was approved
by the Ethics Committee of Ghent University, Belgium
(project 2001/58).
Detection of telomerase activity. For telomerase activity
analysis, the surgical specimens were immediately frozen in
liquid nitrogen and stored until use. Protein extracts were
prepared from frozen samples in 100-250 μl ice-cold
extraction buffer [10 mM Tris-HCl (pH 7.5), 1 mM MgCl2,
1 mM ethylene glycol tertraacetic acid (EGTA), 0.1 mM
benzamidine, 0.5% CHAPS, 5 mM ß-mercaptoethanol, 10%
glycerol], depending on the size of tumour sample. After
30 min incubation on ice, lysates were centrifuged at
13500 rpm for 20 min at 4˚C, and 60-200 μl from each super-
natant was collected. Protein content in each lysate was
measured using the Bradford assay (Bio-Rad Laboratories,
Nazareth Eke, Belgium) and adjusted to 600 ng/μl. Aliquots
of 40 μl protein extracts were frozen in liquid nitrogen.
Telomerase enzymatic activity was determined using the
Telomeric Repeat Amplification Protocol (TRAP) of the
TRAPeze Telomerase Detection Kit (Chemicon, Heule,
Belgium). Briefly, 1.2 μg protein extract was incubated in
50 μl reaction mixture containing 5 μl 10X TRAP reaction
buffer, 1 μl 50X dNTP Mix, 1 μl TS primer (5'-AATCCGTC
GAGCAGAGTT-3'), 1 μl Primer Mix (RP primer 5'-GCGC
GG[CTTACC]3CTAACC-3', K1 primer and TSK1 template
for internal control), and 2 units TaqDNA polymerase at
30˚C for 30 min for telomerase-mediated extension of the TS
primers. Reaction mixtures were subjected to 30 cycles using
the following conditions: 94˚C for 30 sec, 59˚C for 30 sec
and 72˚C for 30 sec. Twenty-five microliters of each poly-
merase chain reaction (PCR) sample was analysed by electro-
phoresis on 10% polyacrylamide-urea gels and visualized
with SYBR-Green I nucleic acid gel stain by means of an
ultraviolet (UV) transilluminator. Telomerase activity is
defined as an incremental ladder. The inclusion of an internal
control, a synthetic DNA construct added to the samples and
which is amplified with the TS and RP primers to generate a
36-bp product, aided the detection of false negatives, which
can be the result from the presence of PCR inhibitors in the
extracts. An immortal cell line derived from a glioblastoma
multiforme showed telomerase activity and was used as
positive control. As negative control lysis buffer replaced
cDNA.
Immunohistochemical evaluation for hTERT. Paraffin-
embedded tissue sections (4-μm) from intracranial menin-
giomas were prepared for examination by immunohisto-
chemical procedures. Slides were heated in sodium citrate
buffer (10 mM, pH 6.0) for 30 min in a microwave oven at
the highest power (700 W, Amana, Newton, IA, USA) for
high temperature antigen unmasking. The endogenous per-
oxidase activity was blocked by 3% H2O2 (Eurolab, Leuven,
Belgium) in distilled water for 10 min at room temperature.
The standard streptavidin-biotin-peroxidase complex method
was performed, employing antibodies against hTERT (1:50
dilution; clone 44F12; Novocastra, Newcastle upon Tyne,
UK). hTERT expression was defined as the ratio of cells
with immunoreactivity for 1000 tumour cells for biopsies
and as positive/negative for cultures. Subsequently, samples
were incubated with biotinylated rabbit anti-mouse, 1:200 for
30 min, followed by the third incubation with streptavidin-
biotin-peroxidase complex, 1:200 for 30 min. Visualization
of the complex was realized with diaminobenzidine (DAB)
and sections were counterstained with haematoxylin. A
glioblastoma multiforme, positive for hTERT, was used as
positive control, whereas normal brain tissue and antigen-free
buffer of the positive control as a negative control. hTERT
percentages were calculated as mean percentage values by
counting nuclei of tumour cells in three positive areas of a
single tumour for thousand cells.
Telomere length analysis (Fig. 1). We followed standard
methodology for telomeres sizing (22-24). Genomic DNA
was double digested with respectively 5 U RsaI and 10 U
HinfI for >3 h at 37˚C and subsequently fragmented by Field
Inversion Gel Electrophoresis (between 1 and 25 kb) on a 1%
agarose gel. Samples were analysed in triplicate. Fractionated
DNA was immobilized on positively charged nylon mem-
branes after denaturation and neutralization. Southern blots
were simultaneously hybridised overnight at 42˚C with a P32
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Figure 1. A blot after hybridisation with a telomere specific probe. The first
and last lanes are DNA markers applied for molecular weight calibration
[left, low molecular weight marker (LMW, 1-12 kb); right, high molecular
weight marker (HMW, 8-48 kb)]. Average telomere length from a lysis of
tumour cells is measured as mean telomere length (23).
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radiolabelled 5-mer synthetic oligonucleotide telomeric probe
and radiolabelled high (8-48 kb) and low (1-12 kb) molecular
weight DNA markers (Invitrogen). Corresponding molecular
weights were calculated on the basis of DNA marker
calibration curve.
Statistical analysis. All statistical analysis was carried out
using SPSS for windows version 12.0 (SPSS Inc., Chicago,
IL, USA). The categorized variables entered into the analysis
were patients' histological subtype, telomerase activity, hTERT
protein expression and telomere length. A Mann-Whitney
test was used to analyse the association between histo-patho-
logical grading, telomerase activity, hTERT protein expression
and telomere length. The level of significance was set at
p<0.05.
Results
A general presentation for the results concerning telomerase
activity, hTERT protein expression and telomere length is
given in Table I. There were 53 intracranial tumours (34
benign meningiomas, 3 atypical meningiomas, 2 malignant
meningiomas, 2 low-grade astrocytomas, 1 anaplastic astro-
cytoma and 11 glioblastomas).
Telomerase activity (Table I). Forty-one cases of intracranial
tumours (30 benign, 3 atypical and 2 malignant meningiomas;
2 low-grade astrocytomas and 4 glioblastomas) were analysed
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Table I. Telomerase activity, hTERT protein expression and
telomere length in intracranial tumours (34 benign, 3 atypical
and 2 malignant meningiomas; 2 low-grade and 1 anaplastic
astrocytoma; 11 glioblastoma multiforme).
–––––––––––––––––––––––––––––––––––––––––––––––––
hTERT
Telomerase labeling Telomerase
No. activity index (%) length (kb)
–––––––––––––––––––––––––––––––––––––––––––––––––
Benign meningiomas (WHO grade I)
1 Neg 0.0 6.972
2 Neg 0.8 6.716
3 Neg 0.0 8.749
4 Neg 0.0 8.592
5 Pos 11.9 7.911
6 Neg 0.0 8.031
7 Neg 0.0 6.006
8 Neg 29.6 7.444
9 Neg 0.0 4.794
10 Neg 28 5.329
11 - 72.7 14.019
12 Neg 1.1 5.055
13 - 76.2 9.278
14 Neg 0.0 6.701
15 - 8.3 7.779
16 Neg 47.1 5.989
17 - 72.3 7.361
18 Neg 56.6 6.720
19 Neg 60.6 6.258
20 Neg 0.0 6.900
21 Neg 0.0 7.321
22 Neg 8.0 7.635
23 Neg 0.0 6.222
24 Neg 0.0 3.694
25 Neg 0.0 5.852
26 Neg 0.0 7.270
27 Neg 0.0 8.163
28 Neg 21.6 5.764
29 Neg 13.1 7.977
30 Neg 9.1 6.062
31 Neg 2.2 6.846
32 Neg 0.0 8.046
33 Neg 0.0 8.489
34 Neg 0.0 7.653
Atypical meningioma (WHO grade II)
35 Neg 25.6 4.469
36 Neg 0.6 4.807
37 Pos 52.1 6.532
Malignant meningioma (WHO grade III)
38 Neg 26.4 9.772
39 Pos 64.5 3.171
Astrocytoma LG (WHO grade II)
40 Neg 0.0 14.31
41 Neg 9.0 9.236
Table I. Continued.
–––––––––––––––––––––––––––––––––––––––––––––––––
hTERT
Telomerase labeling Telomerase
No. activity index (%) length (kb)
–––––––––––––––––––––––––––––––––––––––––––––––––
Anaplastic astrocytoma (WHO grade III)
42 - 0.3 4.903
Glioblastoma multiforme (WHO grade IV)
43 Neg 70.0 4.703
44 Pos 60.0 6.826
45 Pos 49.0 7.843
46 Pos 88.6 5.079
47 - 73.6 3.415
48 - 19.3 6.523
49 - 9.2 8.326
50 - 62.0 4.269
51 - 10.7 2.539
52 - 78.2 5.149
53 - 68.7 8.764
Telomere length in normal intracranial tissue (kb)
Meninges 11.3090 9.7589
Brain tissue 8.833 10.074
11.801 9.697
–––––––––––––––––––––––––––––––––––––––––––––––––
Neg, negative; Pos, positive; -, not available.
–––––––––––––––––––––––––––––––––––––––––––––––––
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for telomerase activity. Telomerase activity was not examined
for 12 of the 53 cases because no part of the biopsy was stored
in the liquid nitrogen. Overall, telomerase activity was detected
in 6 of 41 tumours (14.6%). One of 30 (0.03%) benign
meningiomas, 1 of 3 (33.3%) atypical meningiomas and 1 of
2 (50%) malignant meningiomas expressed telomerase activity.
Within the group of gliomas, neither 1 of the 2 low-grade
astrocytomas and 3 of 4 screened glioblastomas possessed
active telomerase. The number and percentage of intracranial
tumours with telomerase activity increased in the higher
histopathological grades. Thus, telomerase activity strongly
correlated (P<0.001) with the histopathological grading of
the tumours by the WHO-classification.
Detection of hTERT-protein. The hTERT labelling indices
for all intracranial tumour samples are presented in Table I.
hTERT protein staining was seen in the nucleolar region of
tumour cells. Heterogeneity and intensity of hTERT staining
varied depending on the tumour. Positive cells were clustered
together surrounded with non-stained cells. Twenty-two of
39 (56.4%) meningiomas were positive for the 44F12 anti-
body against hTERT. Within this group, there were 17 of 34
(50%) benign meningiomas, the 3 (100%) atypical menin-
giomas and all (100%) malignant meningiomas. The mean
hTERT labelling index (LI) for all 22 hTERT positive
meningiomas was 31.3% (SD=26.5). The mean hTERT LI
for the 17 benign hTERT positive meningiomas was 30.5%
(SD=27.6). The atypical meningiomas had a mean hTERT LI
of 26.1% (SD=25.7) and the malignant meningiomas 45.5%
(SD=26.9).
One of 2 low-grade astrocytomas was positive for hTERT
with 9% of tumour cells labelled. The anaplastic astro-
cytoma had an hTERT expression of 0.3% of the tumour
cells. All the glioblastomas were positive for hTERT and the
mean hTERT LI was 53.6% (SD=28.0). The difference for
hTERT staining between hTERT positive benign menin-
giomas and glioblastomas is statistically significant (P<0.05).
Telomere length measurement (Table I and Figs. 1 and 2).
Telomere length appears as a smear on a Southern blot gel
because the amount of TTAGGG repeats at the (sub)telo-
meric regions varies on the different chromosomes and the
different cells. Also, the telomere length varies from cell to
cell within a tumour.
We analysed the mean telomere length of 53 tumour
biopsies of intracranial tumours. Also samples of meningeal
and brain tissue from fresh corpses were analysed. These
samples were collected from the Anatomical department of
the university and included brain tissue and meninges. Samples
were analysed twice to verify our results.
The mean telomere length of intracranial tissue from
healthy persons was 10.245 kb (SD=1.11). This mean length
was 10.534 kb (SD=1.096) for the meninges, 10.316 kb
(SD=2.099) for grey matter and 9.885kb (SD=0.266) for
white matter.
The mean telomere length for the 39 meningiomas was
6.983 kb (SD=1.869). For the 34 benign meningiomas, we
found a mean length of 7.165 kb (SD=1.724). The mean
telomere length for the 3 atypical meningiomas was 5.269 kb
(SD=1.107) and 6.472 kb (SD=4.668) for the malignant
meningiomas.
For the low-grade astrocytomas, in one of the samples a
mean telomere length was measured of 14.310 kb, while the
telomere length for the other was 9.236 kb. The anaplastic
astrocytoma had a mean length of 4.903 kb. For the 11
glioblastomas the mean telomere length was 5.767 kb
(SD=2.042).
The telomere length was significantly shorter for the
group of meningiomas and gliomas (P<0.001), in comparison
to the normal intracranial tissue, with the exception of one
low-grade astrocytoma.
Discussion
In telomerase positive cells telomere length is balanced by
telomere shortening due to cell division and telomere
elongation by telomerase. In mortal cells, telomeres shorten
during proliferation and hence can be considered as a marker
for the replicative capacity of cells in vitro (22). This capacity
keeps tumour cells proliferating and growing by the stabili-
zation of their telomeres which is essential to maintain the
unlimited dividing potential and to escape ‘crisis’ (25). At
crisis, the telomeres are at critical length, and the integrity
of the chromosomes declines with every subsequent cell
division. Telomere length is maintained by telomerase activity
and can be influenced in different ways and by various
factors (26). From literature it is clear that telomerase activity
can be regarded as a prognostic marker for malignancy
(12,13,16). In contrast to malignant intracranial tumours,
benign meningiomas seldom express telomerase activity.
As telomeres are essential for DNA replication and
control of cell division (1), the regulation of their length has
been a focus of research on tumourigenesis (13,14). It has
been demonstrated that telomere shortening, which occurs at
every successive cell division in somatic cells, is stopped in
most tumours, which leads to immortalisation through the
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Figure 2. Telomere length in 53 intracranial tumours compared with normal
intracranial tissue. Telomere length was determined by Southern blotting.
The mean distribution of the different tumour types for telomere length lies
under normal intracranial tissue with the exception of low-grade astro-
cytomas.
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activation of telomerase. The presence of telomerase activity
indicates the capacity for unlimited cell proliferation (27).
In this study, we investigated the possible link between
telomerase activity, hTERT expression and telomere length
in intracranial tumours. The specificity for immunostaining
against hTERT has been criticized although the sensitivity
posed no problems (28). For them NCL-hTERT was a
marker for nucleolin. Although, hTERT and nucleolin share
the same intracellular distribution and their nucleolin
demonstrates another molecular weight than that found by
others.
We found a significant shortening of the telomeres in the
group of meningiomas and gliomas as compared with normal
intracranial tissue. Fig. 2 represents the attrition of telomeres
for the different groups of tumours. A shortening is visible
for the meningiomas in comparison to normal meninges.
Moreover, a clear shortening is visible for the glioblastomas
as compared to normal intracranial tissue and benign menin-
giomas. Cells from highly proliferating tumours such as glio-
blastomas present higher mitotic activity than benign slow
proliferating tumours. As a result, the telomere will shorten
quicker in glioblastomas than in benign meningiomas. A
high expression of hTERT implies that telomeres could be
stabilized or elongated by active telomerase. All glio-
blastomas expressed hTERT and 75% of the analysed
samples had active telomerase. Only half of the benign
meningiomas expressed hTERT and the labelling indexes
were lower than the group of gliomas. Telomere ends of
tumour cells from benign meningiomas shorten at ease
because of their slower growth. The ‘crisis’ situation is
leading to apoptosis (5,6). Only one benign meningioma had
active telomerase (0.03%). Because the three atypical
meningiomas had shorter telomeres than the benign menin-
gioma, they seem to be in a further state of progression with
higher proliferation and mitosis. hTERT was detected in all
three atypical meningiomas and one had active telomerase.
One of two malignant meningiomas had active telomerase
and both expressed hTERT. The malignant meningioma with
active telomerase had remarkable short telomeres as compared
to normal intracranial tissue and the benign meningiomas.
Chen et al hypothesized that telomerase activity can be
regulated and temporary turned-off, as the telomeres are
longer again (13). In our study, we found longer telomeres in
one of the two low-grade astrocytomas. One of the lengths
was even longer than the normal intracranial tissue. This was
remarkable because there was no expression of hTERT or
active telomerase. Our findings support the hypothesis that
sufficient (hTERT-mediated) telomere stabilization is
achieved late in tumourigenesis after extensive cell prolife-
ration and telomere shortening has already taken place (29).
In this respect, telomere maintenance or even elongation
seem to be essential for the tumour to maintain its (indefinite)
proliferative capacity and to continue further tumour pro-
gression and invasion (1,26). In normal somatic cells, when
telomeres become critically shortened, these enter a growth
arrest state. Longer telomeres provide the cell more mitotic
potential. It is supposed that there is a mechanism that
regulates telomerase activity and telomere length (30,31).
When the length is long enough for proliferation, telomerase
activity subsides. Because glioblastomas are high proliferating
tumours, they keep their telomere length steady  with active
telomerase. Telomerase and telomere length serve as
indicators for the ability of each tumour to compensate for
replicative telomere losses (32,33).
The anaplastic astrocytoma had short telomeres but hardly
any expression of hTERT. This tumour could be in a further
state of progression leading to active telomerase towards a
classification of a secondary glioblastoma multiforme.
Expression of hTERT does not mean activation of the
telomerase complex but is one of the crucial steps towards
the activation (17). Hiyama et al found a correlation between
the length of telomeres and the prognosis in medullo-
blastomas (34). The author concluded that short telomeres
are linked to a further state of progression and a more
aggressive behaviour for these tumours. Also other studies on
telomere length for intracranial tumours found a shortening
of the telomeres for telomerase positive tumours (14,35). In
our study, most tumours (96%) had shorter telomeres
compared to normal intracranial tissue. Shorter telomeres in
cancer tissue compared to normal tissue are indicative for
extensive tumour cell proliferation. However, telomere
stabilization by telomerase is inevitable at a critical point of
telomere shortening to prevent the onset of crisis and
senescence (26).
These results indicate that telomerase activation may be a
critical step in the pathogenesis of gliomas and meningiomas.
Shortening of the telomere length also indicates a high
potential for malignant behaviour in these tumours. In our
series, telomerase activity was detected in 2 of 5 specimens
(40%) of atypical and malignant meningiomas. Compared
to benign meningiomas, 1 out of 30 cases was positive for
telomerase activity, this difference speaks for a late activation
of telomerase in tumour progression.
Detectable telomerase activity and shortened telomere
length are clinically relevant because the presence of these
factors may suggest that the tumours contain a population of
cells with the capacity for unlimited proliferation (13).
Telomere length was reduced in the high-grade tumours,
whereas it was compatible with that of normal brain tissues
in the low-grade astrocytomas, suggesting that telomerase
activity with shortened telomeres correlates with the aggressive
growth of high-grade intracranial tumours.
We conclude that telomere length cannot be used as a
putative prognostic marker on its own but should be linked
with hTERT expression and telomerase activity. There are
signs for alternative mechanisms of telomere elongation
(cases 11 and 40 in Table I), although most tumours have
critically shortened telomeres.
These findings suggests that telomerase activity and
hTERT, together with the telomere length can be an index
of malignant potential or malignancy itself in intracranial
tumours.
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